Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis by Yaylalı, Volkan et al.
Comparative study of 0.1%
olopatadine hydrochloride and
0.5% ketorolac tromethamine in
the treatment of seasonal allergic
conjunctivitis
Volkan Yaylali, Ibrahim Demirlenk, Sinan Tatlipinar, Davut
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ABSTRACT.
Purpose: To compare the therapeutic effects of two ophthalmic solutions (0.1%
olopatadine hydrochloride and 0.5% ketorolac tromethamine) with different
pharmacological mechanisms on the clinical signs and Symptoms of seasonal
allergic conjunctivitis (SAC).
Methods: Forty patients with the signs and symptoms of SAC (i.e. hyperaemia,
itching, mucus discharge, tearing) were included in this placebo-controlled, ran-
domized, parallel group, single centre study. In group 1 (20 patients) one eye of
each patient was treated with olopatadine and the other with placebo. In group 2
(20 patients) one eye of each patient was treated with ketorolac solution and the
other with placebo. The principal signs and symptoms of SAC (hyperaemia and
itching) were evaluated at 30mins and at 2, 7 and 15 days.
Results: In group 1, both parameters improved significantly in eyes treated with
olopatadine compared with those receiving placebo at all control examinations
(all p < 0.05). Similarly, eyes treated with ketorolac showed significant reductions
in signs and symptoms compared with those receiving placebo (all p < 0.05). When
the clinical parameters of eyes treated with olopatadine were compared with
those treated with ketorolac, the mean score of hyperaemia was found to be
lower in the olopatadine group, but the difference was not statistically significant
(all p > 0.05). However, the itching score was significantly lower in the olopata-
dine group from the second day through to the end of the study (p < 0.05).
Conclusions: Both olopatadine and ketorolac ophthalmic solutions were found to
be effective in alleviating the clinical signs and symptoms of SAC compared to
placebo. However, olopatadine reduces ocular itching significantly more than
ketorolac.
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Introduction
Seasonal allergic conjunctivitis (SAC)
or hay fever is a common allergic dis-
ease typically elicited by airborne aller-
gens such as pollen, grass, weeds and
animal dander (Abelson & Schaefer
1993). It is a type 1 hypersensitivity
reaction mediated by IgE in response
to these environmental antigens. The
principal symptom of SAC is ocular
itching (Abelson & Schaefer 1993).
Other signs and symptoms include con-
junctival hyperaemia, tearing, mucus
discharge, chemosis and lid oedema.
Mast cells play an important role in
the pathophysiology of this condition.
When specific allergens bind to sensi-
tized mast cells in the conjunctiva,
degranulation of mast cells, and release
of preformed (histamine, eosinophil
chemotactic factor, tryptase) and
newly synthesized mediators (prosta-
glandins, leukotrines) occur. Hence,
typical signs and symptoms of SAC
appear. Histamine, which is a pre-
formed agent, is accepted as the predom-
inant mediator (Berdy et al. 1991).
On the other hand, prostaglandin D2
is produced by the arachidonic acid
pathway, and has a role in the patho-
genesis of SAC (Woodward et al. 1995).
Prostaglandin D2 has been shown to
induce conjunctival hyperaemia, oedema
and mucus discharge; prostaglandins,
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particularly D2 and E2, have a
pruritogenic effect on the conjunctiva
(Woodward et al. 1995).
Topically applied ophthalmic agents
are the principal treatment method for
SAC. Currently available topical drugs
include H1 antihistamines such as
levocobastine, H1 antihistamine-
vasoconstrictor combinations such as
antazoline-naphazoline, mast cell stabi-
lizors such as cromolyn sodium and
lodoxamide, and non-steroidal anti-
inflammatory drugs (NSAIDs) which
inhibit prostaglandin synthesis, such
as ketorolac tromethamine. Inhibition
of prostaglandin synthesis, including
prostaglandins D2 and E2, may play a
role in the treatment of SAC. Ketorolac
is an NSAID approved in the USA for
the relief of ocular itching associated
with SAC which works by inhibiting
the prostaglandins’ pruritogenic effects
on the conjunctiva. A new topical drug,
olopatadine, has been shown to have a
dual action, in terms of both mast cell
degranulation inhibition and histamine
H1 receptor blockage (Sharif et al.
1996; Yanni et al. 1996; Abelson 1998;
Abelson & Spitalny 1998; Deschenes
et al. 1999). This agent has a rapid
onset due to antihistamine activity and
prolonged duration of action due to
mast cell stabilization, which allows
for a twice daily dosage.
The aim of the current study was to
compare the therapeutic effectiveness of
two ophthalmic solutions (0.1% olopata-
dine hydrochloride; Patanol1 (Alcon
Laboratories, Fort Worth, TX, USA)
and 0.5%ketorolac tromethamine; Acu-
lar1 (Allergan, Irvine, CA, USA) with
differentpharmacologicalmechanismson
the clinical signs and symptoms of SAC.
Material and Methods
A total of 40 patients with the signs and
symptoms of SAC (ocular itching,
hyperaemia, mucus discharge and tear-
ing) were involved in this placebo-
controlled, randomized, parallel group,
single centre study. All subjects had a
history of SAC over the previous
2 years and showed the same classical
signs and symptoms of SAC during the
study period. None of the patients had
a systemic or ocular (dry eye, uveitis,
viral-bacterial infection) illness, and
none had received systemic or topical
ocular medication during the 4weeks
prior to the study. All patients started
and completed the study within the
month of April in order to avoid a
major variance in allergen counts. In
our region, April is the period when
patients with SAC display maximum
signs and symptoms, indicating a
heavy allergen exposure.
Group 1 comprised 20 patients. One
eye of each of these patients received
olopatadine and the other eye received
placebo (Tears Naturale II1, Alcon,
Fort Worth, TX, USA), both twice
daily. Group 2 (20 patients) used ketor-
olac solution in one eye and the placebo
(Tears Naturale II1, Alcon) in the fel-
low eye, four times daily. Informed
consent was obtained from all patients.
In order to achieve better rates of com-
pliance, patients were given 15-day
timetables indicating the control days
and drop instillation times. Patients
were asked to mark each medication
administration on these schedules and
these lists were checked at each control
visit.
Clinical signs and symptomswere evalu-
ated at baseline, and at 30mins and 2,
7 and 15days. The main parameters
assessed were ocular itching and hyperae-
mia. The grading of signs and symptoms
are shown in Table 1.
Statistical analysis was performed
using the paired t-test. A p-value
< 0.05 was accepted as statistically sig-
nificant.
Results
Of the 40 subjects, 21 were male and 19
were female. Their average age was
19 years (range 15–25 years). All
patients completed the study. Overall
topical drop application compliance
was 100% in the olopatadine group
and 90% in the ketorolac group (i.e.
two patients missed three applications).
The mean scores of the clinical para-
meters were computed for each exami-
nation (Table 2). The baseline scores
were found to be similar in both groups
(p > 0.05). In group 1, both itching and
hyperaemia improved significantly in
eyes receiving olopatadine solution
compared to placebo eyes at all control
examinations (p < 0.05) (Figs 1 and 2).
Similarly, eyes receiving ketorolac solu-
tion showed a significant reduction in
signs and symptoms compared to pla-
cebo eyes at all examinations (p < 0.05)
(Figs 1 and 2). When the mean scores of
olopatadine treated eyes were com-
pared to the scores of ketorolac treated
eyes, the mean scores of hyper-
aemia were found to be lower in the
olopatadine group, indicating better
therapeutic effectiveness, although
the difference did not reach statistical
significance (p¼ 0.154, 0.9, 0.65,
0.79, 0.79, for baseline, 30mins, 2,
7 and 15 days scores, respectively)
(Figs 1 and 2). Itching scores, however,
were found to be significantly lower
in the olopatadine group at 2, 7 and
15 days (p¼ 0.339, 0.446, 0.018, 0.007,
0.036, for baseline, 30mins, 2, 7 and
15 days, respectively) (Figs 1 and 2).
Discussion
Both olopatadine and ketorolac
ophthalmic solutions were found to be
effective in the treatment of SAC com-
pared to placebo. These two drugs act
Table 1. Scoring of signs and symptoms of allergic conjunctivitis.
Score
Itching* 0 None
1 Intermittent tickling sensation, involving more than corner of eye
2 Mild, continuous itch without desire to rub
3 Severe itch with desire to rub
Hyperaemia 0 None
1 Mild, slightly dilated blood vessels, pink in colour, may be quadrantal
2 Moderate, more apparent vessel dilatation, vessel colour is more intense, involves most of vessel bed
3 Severe, numerous and obvious dilated blood vessels, colour deep red, not quadrantic
* Itching was scored by the patients.
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via different pharmacological mechan-
isms. Olopatadine is a new topical ocu-
lar dibenzoxepin derivative (Yanni et al.
1996). It inhibits the release of pre-
formed and newly synthesized inflam-
matory mediators from mast cells upon
allergen challenge, and also has antihis-
taminic properties towards H1 recep-
tors. Its dual activity is an advantage
and the drug may be used both as a
therapeutic and prophylactic agent.
The dual action also renders the drug
superior in terms of clinical effective-
ness, rapid onset and length of duration
of action (Abelson 1998; Abelson &
Spitalny 1998; Deschenes et al. 1999).
On the other hand, ketorolac is an
NSAID; it works through the inhibi-
tion of cyclooxygenase, which produces
prostaglandins. Prostaglandin D2 is
among the newly synthesized mediators
released by mast cells following antigen
stimulation, and inhibition of the pro-
duction of this mediator can decrease
the signs and symptoms of SAC
(Woodward et al. 1995). Antiprurito-
genic and antihyperaemic actions of
ketorolac in the treatment of SAC can
be explained by inhibition of prosta-
glandin synthesis, particularly prosta-
glandins D2 and E2 (Woodward et al.
1995).
Prior placebo-controlled, rando-
mized studies have demonstrated the
effectiveness of olopatadine in the
treatment of allergic conjunctivitis
(Abelson 1998; Abelson & Spitalny
1998; Deschenes et al. 1999). Ketorolac
ophthalmic solution has also been
found to be more effective than placebo
in the therapy of SAC (Ballas et al.
1993; Tinkelman et al. 1993).
In a previous study, the efficacy of
olopatadine ophthalmic solution was
compared to that of ketorolac solution
in a clinical model of acute allergic con-
junctivitis (Deschenes et al. 1999). The
study used the provocative antigen
challenge model and subjects were ran-
domized to receive either olopatadine
in one eye and placebo in the contral-
ateral eye, or ketorolac in one eye and
placebo in the fellow eye. At 27mins
after drug administration, the eyes
were challenged with allergen, and ocu-
lar itching and hyperaemia were graded
at 3, 10 and 20mins. Olopatadine was
found to be significantly more effective
than ketorolac in the alleviation of the
clinical parameters studied. This study
has some differences compared to our
trial. It was performed as a clinical
Table 2. Mean itching and hyperaemia scores (SD).
Baseline 30mins 2nd day 7th day 15th day
Itching
Olopatadine 2.3 (0.9) 0.4 (0.8) 0.05 (0.2) 0 0
Placebo 2.2 (1.1) 1.3 (1.2) 1.1 (1.2) 1 (1.1) 1 (1.1)
p-value 0.76 0.011 0.0001 0.0001 0.0001
Ketorolac 2.5 (0.5) 0.6 (0.8) 0.4 (0.6) 0.3 (0.4) 0.2 (0.4)
Placebo 2.6 (0.5) 1.8 (1.1) 1.4 (0.9) 1.4 (1.0) 1.2 (1.0)
p-value 0.791 0.0001 0.001 0.0001 0.0001
Hyperaemia
Olopatadine 2.0 (0.7) 1.2 (0.6) 0.7 (0.5) 0.4 (0.5) 0.3 (0.4)
Placebo 2.1 (0.7) 1.8 (0.7) 1.6 (0.5) 1.4 (0.6) 1.3 (0.7)
p-value 0.664 0.014 0.0001 0.0001 0.0001
Ketorolac 2.2 (0.5) 1.2 (0.7) 0.8 (0.8) 0.5 (0.6) 0.4 (0.6)
Placebo 2.2 (0.6) 2.0 (0.7) 1.8 (0.8) 1.8 (0.7) 1.8 (0.7)
p-value 0.796 0.002 0.0001 0.0001 0.0001
Fig. 1. Ocular itching scores. (A) Olopatadine versus placebo. (B) Ketorolac versus placebo.
(C) Olopatadine versus ketorolac.
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model of acute allergic conjunctivitis
elicited by antigen challenge, the drug
was applied once and its effectiveness
was evaluated over a 20-min period.
Our study included patients with SAC
and the drugs were administered and
their efficacy evaluated over a 15-day
period. According to Deschenes et al.
(1999), ketorolac did not significantly
reduce itching and increased the hyper-
aemia compared to placebo. The
authors explained ketorolac’s lack of
effectiveness in the inhibition of allergic
response in the human conjuctiva on
the basis that either prostaglandin D2,
which is important in guinea pig aller-
gic conjunctivitis, might have a limited
role to play in human allergic conjunc-
tivitis, or that the dosing regimen
employed (one application only,
approximately 30mins before allergen)
was not enough for the drug to show its
effect. The first explanation contradicts
other studies which have clinically
demonstrated the effectiveness of keto-
rolac in the treatment of SAC (Ballas
et al. 1993; Tinkelman et al. 1993).
In these studies, ketorolac was used
four times daily for 1week, in a similar
manner to our study. In our study, the
effectiveness of ketorolac was observed
right from the 30-min check, a finding
which contradicts the second proposal
made by Deschenes et al. (1999). The
paradoxical increment in the hyper-
aemia was explained by ocular irritation
upon ketorolac solution administration
(Deschenes et al. 1999).
The mean scores for hyperaemia
were found to be lower in the olopata-
dine group than in the ketorolac group
in our study. As for ocular itching, the
difference reached statistical signifi-
cance, indicating that olopatadine was
superior to ketorolac in inhibiting ocu-
lar pruritus. The higher clinical effect-
iveness of olopatadine compared to
ketorolac in alleviation of signs and
symptoms of SAC, particularly of itch-
ing, may be explained by the dual
action of this drug. Histamine is
accepted as the principal mediator in
allergic conjunctivitis, and is responsi-
ble for the characteristic symptom of
itching (Berdy et al. 1991). It has been
shown that selective stimulation of H1
receptors in the conjunctiva results in
itching (Weston et al. 1980). However,
other mediators such as prostaglandins
D2 and E2 have also been shown to
have pruritogenic properties (Woodward
et al. 1995). Ketorolac, unlike olopatadine,
does not inhibit mast cell degranulation
and does not possess antihistamine
activity. Although ketorolac inhibits
pruritogenic prostaglandin synthesis,
and thus has antipruritogenic effective-
ness in the treatment of SAC, the
resultant anti-itching effect is less than
that of olopatadine, which is a potent
antihistaminic agent.
Our study has some limitations.
Firstly, this is an environmental study
and thus differs from the conjunctival
allergen challenge (CAC) model. The
CAC model was reported to provide
standardized, reproducible results,
thereby avoiding the possible variabil-
ity in signs and symptoms inherent in
naturally occurring conditions (Abelson
& Spitalny 1998). Our study included
patients who had SAC under natural
conditions, implying that they might
have been exposed to varying amounts
of allergen during the study. In order to
minimize a large fluctuation of pollens,
all subjects were evaluted within the
same month and were observed on the
same day at all control visits. More-
over, the patients included in the study
came from different parts of our region,
both rural and urban, and taking pollen
counts at many different areas would
not have been feasible. It might be
argued that the observed results in this
study were due to decreased allergen
exposure during the study and that the
reduction in placebo scores serves as
Fig. 2. Conjunctival hyperaemia scores. (A) Olopatadine versus placebo. (B) Ketorolac versus
placebo. (C) Olopatadine versus ketorolac.
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evidence of this proposal. Even if the
pollen counts decreased during the
study period, which we do not believe
to be the case, the differences observed
between study drugs and placebo, and
between study medications, cannot be
explained solely on the basis of
decreased antigen exposure. As for
the effect of placebo on the clinical
parameters of SAC, it is well known
that artificial tear preparations have
diluting and flushing effects on
allergens and inflammatory mediators
present on ocular surface. One last
problem related to environmental
studies is the issue of compliance.
In our study, patient compliance was
stimulated by asking each patient to
use a diary.
In conclusion, both olopatadine
and ketorolac ophthalmic solutions
were found to be effective in alleviating
the clinical signs and symptoms of
SAC compared to placebo. However,
the improvement in clinical para-
meters, particularly ocular itching,
was more significant in olopatadine
group.
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Çaybasi M. Park Apt. 20/3
20010 Denizli
Turkey
Tel:þ 90 258 26 55 705
Fax:þ 90 258 24 10 040
Email: volkanyaylali@hotmail.com
ACTA OPHTHALMOLOGICA SCANDINAVICA 2003
382
